Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH’s Robert Gallo

Executive Summary

Formal investigation "is warranted" of Gallo's National Cancer Institute Laboratory, National Institutes of Health Acting Director William Raub announced Oct. 5. The investigation will focus on several aspects of published reports from Gallo's lab, particularly the article by Mika Popovic, et al., published in the May 1984 issue of Science, that first described HIV. The investigation will also conduct tests to determine the origins of the HTLV-IIIB virus that Gallo and his colleagues used to develop the blood test for HIV. Raub noted that the initial inquiry into Gallo's research by NIH's Office of Scientific Integrity "has resolved certain of the publicized allegations and issues or shown them to be without substance. In particular, the inquiry team has concluded that Dr. Gallo had a substantial number of HIV detections and isolations from several different sources at the critical time that HTLV-IIIB (the principal virus isolated by the Gallo laboratory) and LAV (the virus isolated by the Pasteur Institute) were being grown in Gallo's laboratory".

You may also be interested in...



Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel